New Revolutionary Antifungal Drug
A Paradigm Shift In The Treatment Of Invasive Aspergillosis
Status & Progress
PulmoPharma’s Puldium™ is new inhalable combination drug for the treatment of invasive aspergillosis in the lungs.
This kind of combination treatments are known to have a very low or not existing risk of developing drug resistance.
Pre-clinical studies have already shown the efficacy of Puldium™ and its clear superiority over the existing used treatments.
We’re currently doing in vitro/in vivo studies and preparing for a toxicology study and Phase IIa studies.
PulmoPharma is actively looking for collaboration in the R&D phase and future commercial partner(s).
The Problem
Aspergillus fumigatus – a life threatening fungi that is found everywhere and growing resistance to existing drugs – affects over two million people annually. Highly lethal for immunosuppressed hosts.
The treatment of Aspergillus infections today involves the use of three major drug classes, triazoles, polyenes and, echinocandins.
However, since the current treatments for aspergillus are very ineffective, infections and mortality caused by azole-resistant Aspergillus fumigatus are steeply increasing in several countries.
This lack of treatment options gives cause for great concern and underlines the need for new effective drug(s).
Our Solution
The in-vitro studies done in the Department of Clinical Microbiology at Aarhus University Hospital show that PulmoPharma’s PuldiumTM was able to outperform the most widely used current treatments on all five selected fungi types.
It’s very difficult and time consuming to get the exact diagnosis of which fungi type a patient has and therefore the responsible doctors have to make a possibly lethal guess or use a combination of existing, potentially non-effective drugs with pronounced side effects as a result.
Market
Our aim is that PuldiumTM will became the gold standard treatment for all suspected fungi infections in the lungs since it’ll fully eliminate most known variants. PuldiumTM is delivered directly to the lungs using a standard jet nebulizer.
The global antifungals market is expected to grow from $9.98 billion in 2020 to $10.29 billion in 2021 at a compound annual growth rate (CAGR) of 3.1%. The market is expected to reach $13.71 billion in 2025 at a CAGR of 7.4% (ResearchAndMarkets.com report from August 2021).
PulmoPharma aims to revolutionize this growing market of antifungal drugs with PuldiumTM.
Contact us